Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
about
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaEculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaEculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerationsRole of Complement in Autoimmune Hemolytic AnemiaNew Insights in the Pathogenesis of Autoimmune Hemolytic AnemiaComplement inhibitors to treat IgM-mediated autoimmune hemolysisRed blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapyPredictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria.Paroxysmal nocturnal haemoglobinuria. Experience over a 10 years period.Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.Paroxysmal nocturnal hemoglobinuriaParoxysmal nocturnal hemoglobinuria: a single Spanish center's experience over the last 40 yrCompstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy.Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuriaPeptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Management of paroxysmal nocturnal haemoglobinuria: a personal view.Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.Protection of host cells by complement regulators.Complementopathies.Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.Paroxysmal nocturnal hemoglobinuria and eculizumab.Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test.Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.High-Sensitivity Detection of PNH Red Blood Cells, Red Cell Precursors, and White Blood Cells.Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab.Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs.
P2860
Q24193045-F6119EA7-9289-4A3D-8E16-8A6CDF965244Q24201126-37D5C2BA-385F-475D-938C-35D3D95879F0Q26740877-EA6D7B8E-4089-4E65-976B-B54140E13DD9Q26773175-5D10FB93-196D-4BDB-BE69-1161391C2A38Q26773181-6D6B81E5-D6F1-4DE9-A794-8712717EAE19Q26777628-04319E2C-23EE-4D68-82C1-DA7B79D7C227Q27013581-9CF53E9F-AA23-4E9F-8596-6CCECD840117Q33403710-0F5DE403-CCCF-4831-AE3E-8A42BC99DA81Q33411290-1DEB27C2-83CB-4229-B39E-E15D4179C469Q33436512-ACCB0260-A628-41F4-8954-87AB559718B0Q34148715-6FCB3894-6907-42CE-B6EB-3D31FF9109A7Q34431429-F7B93A90-71D1-4885-8625-2BC710371445Q34516330-B6ECED29-7B42-43FE-AB6C-6772DFFF35ECQ35236103-ED19DE4D-6BF9-44D1-9913-0FABFA3064CAQ35252156-A9ACE07F-D4EF-40A2-87D9-079D81543892Q35858087-84EDBE85-D4EF-490A-8D28-1C1F6A632B10Q36187306-65F3E013-6F62-4C97-B712-E6CE7AE54948Q36563619-9695751E-4DC0-4A5C-AD0F-9805C9061D71Q37529706-4EA80250-5DB6-4019-8C1A-64A78B158396Q37552016-3D88902D-EC96-4765-8FE8-298E08F40E34Q37670073-1C4D2860-1D19-4E1D-A166-7ADB71F95D4DQ37724607-9B249F1A-A29A-4EE5-8193-F4B7EFB022B2Q37868639-49F04B91-F2A5-4C7D-8D59-EFAE51F12C02Q37956407-FA479AEA-BE45-4A43-B7AD-853B1CB30CA9Q38156229-6397F95C-60FB-4CBC-A7BD-35E1CFD38CC3Q38991019-5C48809F-09C4-421F-BEC1-EA48E91C09C0Q39142842-B488871C-B462-426C-BC55-A5AE08ABB0CCQ41032734-DC4C960F-4FC2-4568-8135-5447048B1276Q41091207-09392755-DD60-45EA-926C-FA28838F398BQ42832542-53614C62-ED04-44E8-8F7B-E02F5C21728EQ43441251-B8E8BD85-9AC8-4E43-AA28-6811731EA94FQ46433084-2861C6DB-F896-4387-8FB4-E527F2FCCC99Q48078070-5430095D-AF91-45B4-A837-594775600514Q48114152-84169E4E-7EBF-4C30-9BE9-35B72542DFB9Q48152299-5C1DE9C8-077A-42C5-A332-8BF2E3F3E882Q50449096-3B3E6D83-F7F0-47C6-8447-C7E75064CF1DQ52840713-8D2BB6DB-1B7D-4001-A20E-31B48A8361DFQ54919143-D61B8977-8C56-4B7E-954B-85E78F1D2906
P2860
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en-gb
type
label
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en-gb
prefLabel
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en-gb
P2093
P2860
P1433
P1476
Eculizumab prevents intravascu ...... rring through C3 opsonization.
@en
P2093
Anita Hill
Louise Arnold
Matthew J Cullen
Richard Kelly
Russell P Rother
Stephen J Richards
P2860
P304
P356
10.3324/HAEMATOL.2009.007229
P577
2010-02-09T00:00:00Z